Quick Review: Deep Venous Thrombosis
T Fujii, B Phillips

Citation

Abstract

DEEP VENOUS THROMBOSIS (DVT)

VIRCHOW’S TRIAD
- Stasis
- abnormalities of vessel wall
- alterations of the blood coagulation system

Thrombosis occurs when blood coagulation overwhelms the natural anticoagulant mechanisms and the fibrinolytic system; usually occurs at sites of vessel damage, in the region of an anatomical valve

RISK FACTORS:
- Recent Surgery
- Trauma
- Immobilization
- Serious Illness- CHF, CVA, Cancer, IBD
- Chronic Venous Insufficiency
- Hypercoagulability or Thrombophilia
- Exogenous Estrogen Use or Oral Contraceptives
- Pregnancy
- Obesity
- History of Thrombosis

CLINICAL FEATURES:
- Localized swelling, particularly unilateral
- Redness or discoloration
- Pain or tenderness
- Distal edema
- Homan Sign: discomfort in the calf muscles on forced dorsiflexion of the foot

Clinical Diagnosis is NOT accurate

DIFFERENTIAL DIAGNOSIS:
- Baker's Cyst (ruptured)
- Muscle tear or cramp
- Hematoma
- Cellulitis
- Postthrombotic Syndrome
- Superficial Thrombophlebitis

DIAGNOSTIC STUDIES:
Suspicion of a D.V.T. from history and physical examination requires confirmation with further testing

1. Venography:
2. Impedance Plethysmography:
3. Noninvasive
4. Invasive, expensive, can be painful, may produce superficial thrombophlebitis [can be complicated by a D.V.T. (1-2%)]
5. Calf vein thrombi
6. False positive results can occur with chronic heart failure, postoperative leg swelling, or external compression.

1. Venous Ultrasonography:


**TREATMENT:**

Once diagnosis confirmed, begin Treatment.

**GOALS OF TREATMENT:**

To prevent P.E., postthrombotic syndrome, and thromboembolic pulmonary hypertension.

Calf Vein Thrombi:

Therapy controversial, either anticoagulation or close follow-up with serial testing is recommended.

**TREATMENT: HEPARIN**

Continuous IV, Intermittent IV, Intermittent SQ At Least 4-7 Days of IV Therapy Recommended Begin with bolus dose followed by continuous infusion.

1. Maintain PTT 1.5-2.5 times the control value.
2. Important to achieve and maintain therapeutic PTT values.

**SIDE EFFECTS**

1. Thrombocytopenia
2. Osteoporosis
3. Bleeding

**TREATMENT: LOW-MOLECULAR WEIGHT HEPARIN LMWH**

Trials underway for use as outpatient therapy of D.V.T.

**ADVANTAGES**

1. Less bleeding
2. Longer half lives

3. No laboratory monitoring necessary.

**TREATMENT: COUMADIN**

Begin within 24 hours after initiation of heparin.

Maintain PT at INR of 2.0 to 3.0.

Continue IV heparin until INR in therapeutic range for two consecutive days.

Continue Therapy for At Least 3 Months, then Reassess.

- In patients with known, acute, transient risk factor, four to six weeks of therapy adequate if risk factor is no longer present.
- In patients with certain diseases (malignancy) or recurrence, long term therapy is indicated.

**SIDE EFFECTS**

1. Skin necrosis
2. Bleeding

**TREATMENT: THROMBOLYTICS**

Reserved for patients with life-threatening pulmonary embolism or with extensive iliofemoral venous thrombosis & low risk of bleeding.

- Streptokinase
- TPA
- Urokinase

**TREATMENT: INVASIVE INTERVENTION**

VENA CAVAL FILTER

Indications include failed oral anticoagulant therapy, or instances where anticoagulation is contraindicated (bleeding, necrosis, etc).

**SURGICAL THROMBECTOMY**

Indications include chronic thromboembolic pulmonary hypertension and massive pulmonary embolism in patients with contraindications to thrombolytic therapy.

**References**
Author Information

Tisha K. Fujii, DO
Dept. of Trauma & Critical Care, Boston University School of Medicine, Boston Medical Center

Bradley J. Phillips, MD
Dept. of Trauma & Critical Care, Boston University School of Medicine, Boston Medical Center